Dr Judith Michels outlines the current treatments and guidelines for HPV-associated cancers, and considers how outcomes for patients with these malignancies may be improved in the future.1/3 Next Interview
Dr Andrew Sikora outlines the link between HPV and TGF-β, and how this can drive the development of new therapeutic options for HPV-associated cancer.2/3 Next Interview
Dr Krishnansu Tewari summarizes the mechanisms of action and clinical trial data for new and emerging treatment options for patients with HPV-associated cancer.3/3 Take CE/CME Test
Learning Objectives & Overview
In this activity, the expert faculty review the unmet needs for patients with HPV-associated cancers, and the link between HPV and TGF-β, and how this is driving the development of new treatments targeting HPV or TGF-β.
This activity is jointly provided by USF Health and touchIME. read more
This activity has been designed to meet the educational needs of oncologists specializing in the management of gastrointestinal, gynaecological, genitourinary, and head and neck cancers.
All individuals in a position to influence content have disclosed to USF Health any financial relationship with an ineligible organization. USF Health has reviewed and mitigated all relevant financial relationships related to the content of the activity. The relevant relationships are listed below. All individuals not listed have no relevant financial relationships.
Dr Judith Michels discloses: Advisory board fees from from GlaxoSmithKline (Relationship Terminated).
Dr Andrew Sikora discloses: Consultancy fees from F. Hoffman La Roche Ltd.
Dr Krishnansu Tewari discloses: Advisory board/panel fees from AbbVie, AstraZeneca, Clovis, Eisai, Genentech, GlaxoSmithKline/Tesaro and Merck (Relationships Terminated). Consultancy fees from AbbVie, AstraZeneca, Clovis, Eisai, Genentech, GlaxoSmithKline/Tesaro and Merck. Grants/research support from AbbVie, AstraZeneca, Clovis, Genentech, Merck and Regeneron. Speaker’s bureau fees from AstraZeneca, Clovis, Eisai and GlaxoSmithKline.
Angela Massey Hill, PharmD, CPh, RPh has no financial interests/relationships or affiliations in relation to this activity.
Touch Medical Director
Hannah Fisher has no financial interests/relationships or affiliations in relation to this activity.
USF Health Office of Continuing Professional Development and touchIME staff have no financial interests/relationships or affiliations in relation to this activity.
Requirements for Successful Completion
In order to receive credit for this activity, participants must review the content and complete the post-test and evaluation form. Statements of credit are awarded upon successful completion of the post-test and evaluation form.
If you have questions regarding credit please contact firstname.lastname@example.org.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through a joint providership of USF Health and touchIME. USF Health is accredited by the ACCME to provide continuing medical education for physicians.
USF Health designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS) – European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
Advanced Practice Providers
Physician Assistants may claim a maximum of 0.75 Category 1 credit for completing this activity. NCCPA accepts AMA PRA Category 1 CreditTM from organizations accredited by ACCME or a recognized state medical society.
The AANPCP accepts certificates of participation for educational activities approved for AMA PRA Category 1 CreditTM by ACCME-accredited providers. APRNs who participate will receive a certificate of completion commensurate with the extent of their participation.
Date of original release: 20 January 2022. Date credit expire: 20 January 2023.
If you have any questions regarding credit please contact email@example.com.
After watching this activity, participants should be better able to:
- Describe the current unmet needs for patients with advanced HPV-associated cancers
- Recognize the link between HPV infection and TGF-β in HPV-associated cancers
- Recall the mechanisms of action and latest data for agents targeting HPV or TGF-β for the treatment of HPV-associated cancers